Eur Rev Med Pharmacol Sci 2018; 22 (10): 3130-3137

DOI: 10.26355/eurrev_201805_15072

Procalcitonin is useful in driving the choice of early antibiotic treatment in patients with bloodstream infections

R. Murri, I. Mastrorosa, F. Taccari, S. Baroni, F. Giovannenze, C. Palazzolo, S. Lardo, G. Scoppettuolo, G. Ventura, R. Cauda, M. Fantoni

Department of Infectious Diseases, School of Medicine, Catholic University of the Sacred Heart, A. Gemelli Foundation, Rome, Italy. Rita.Murri@unicatt.it


OBJECTIVE: To evaluate whether PCT levels could be used to distinguish among different bacterial and fungal etiologies in patients with documented bloodstream infection (BSI).

PATIENTS AND METHODS: Monocentric retrospective cohort study on patients admitted to the Fondazione Policlinico Gemelli Hospital between December 2012 and November 2015 with BSI. Those who had undergone PCT determination within 48 hours of when the first positive blood culture was sampled were included in the study.

RESULTS: Four hundred and one patients were included in the study. Both the 24h and 48h PCT values were significantly higher in patients with Gram-negative (GN) BSI than in those with Gram-positive (GP) or candida BSI (p at ANOVA = 0.003). A PCT value of > 1 ng/ml was found in 31.5% of patients with GN BSI. Less than 7% of people with candida BSI had PCT level of > 1 ng/ml. At multivariable regression analysis, GN BSI, septic shock, and plasma creatinine were significantly correlated with PCT values.

CONCLUSIONS: PCT may be of value in distinguishing GN BSI from GP, and fungal BSI and PCT values of > 1 ng/ml could be used to prevent unnecessary antifungal treatment.

Free PDF Download

To cite this article

R. Murri, I. Mastrorosa, F. Taccari, S. Baroni, F. Giovannenze, C. Palazzolo, S. Lardo, G. Scoppettuolo, G. Ventura, R. Cauda, M. Fantoni
Procalcitonin is useful in driving the choice of early antibiotic treatment in patients with bloodstream infections

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 10
Pages: 3130-3137
DOI: 10.26355/eurrev_201805_15072